Susquehanna International Group
CYCN icon

Susquehanna International Group’s Cyclerion Therapeutics CYCN Stock Holding History

Susquehanna International Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-85,600
Closed -$287K – 12352
2023
Q4 		$287K Hold
85,600
– – ﹤0.01% 9929
2023
Q3 		$291K Hold
85,600
– – ﹤0.01% 9410
2023
Q2 		$352K Buy
85,600
+81,320
+1,900% +$421K ﹤0.01% 9115
2023
Q1 		$36.8K Sell
4,280
-1,055
-20% -$13.3K ﹤0.01% 11829
2022
Q4 		$70.4K Buy
5,335
+110
+2% +$1.3K ﹤0.01% 11214
2022
Q3 		$90K Buy
5,225
+100
+2% +$1.72K ﹤0.01% 11782
2022
Q2 		$56K Buy
5,125
+1,025
+25% +$14.7K ﹤0.01% 11916
2022
Q1 		$91K Sell
4,100
-185
-4% -$4.46K ﹤0.01% 11974
2021
Q4 		$147K Sell
4,285
-985
-19% -$46.5K ﹤0.01% 11811
2021
Q3 		$324K Buy
5,270
+2,120
+67% +$139K ﹤0.01% 10424
2021
Q2 		$246K Buy
+3,150
New +$197K ﹤0.01% 11174

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's CYCN Position: Q2 2023 in Review

Susquehanna International Group sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 2,259 shares — an estimated $11.7K sold.

Susquehanna International Group first reported a position in CYCN in Q2 2019 and held it in 14 quarters. The position peaked at $313K in Q2 2021. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

  • Susquehanna International Group reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 2,259 Cyclerion Therapeutics shares in Q2 2023, an estimated $11.7K.
  • Susquehanna International Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 14 quarters.
  • Susquehanna International Group's Cyclerion Therapeutics position peaked at $313K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.